Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria (FOSPIP)

Jomaa Pharma

Status and phase: Unknown; Phase 2

Conditions: Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria

Treatments: Drug: Fosmidomycin-Piperaquine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02198807

JP017

Details and patient eligibility

About

The objective of this study is to explore the role of fosmidomycin and piperaquine as non-artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum when administered over three days.

Together, fosmidomycin and piperaquine fulfil the WHO criteria for combination therapy by meeting the three key parameters of having different modes of action and different biochemical targets while exhibiting independent blood schizonticidal activity. Like the artemisinins, fosmidomycin is fast-acting, has an excellent safety record and is active against existing drug-resistant parasites. Piperaquine has a long half life protecting fosmidomycin as a much shorter lived molecule against selection of resistant parasites and will provide post-treatment prophylaxis.

Enrollment: 100 patients

Sex: All

Ages: 1 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects aged 1 to 60 years inclusive
• Body weight between 5kg and 90kg inclusive
• Acute manifestations of a mono-infection with Plasmodium falciparum as determined by either a rapid diagnostic test for adults or microscopically confirmed by an asexual parasitaemia of 1,000 to 150,000/uL and fever with an axillary temperature of > 37.5 degress C or oral/rectal/tympanic temperature of > 38.0 degrees C or history of fever during the previous 72 hours
• Compliance with contraceptive measures throughout the study period of 63 days in females of child bearing potential

Exclusion criteria

To be eligible for inclusion in the study, subjects must NOT meet any of the following criteria:

• Signs of severe/complicated malaria according to WHO criteria

• Pregnancy as excluded by negative serum human chorionic gonadotrophin (hCG) test

• Lactation

• Mixed Plasmodium infection

• Severe vomiting on three or more occasions in the previous 24 hours

• Severe diarrhoea on four or more occasions in the previous 24 hours

• Concomitant disease masking assessment of response including

  • abnormal liver function tests with bilirubin > 40 µmol/L, aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels > x 2 upper limit of normal
  • impaired renal function with creatinine level > x 2 upper limit of normal
  • haemoglobin level < 7.5g/dl
  • white cell count > 12000/µL

• History of cardiovascular disease including arrhythmia with QTc interval ≥ 450msec, respiratory disease including active tuberculosis, hepatic disease including jaundice, renal failure, malignancy, neurological disorders including convulsions and psychiatric disturbances

• History of immunological disease including Hepatitis A, B and C and HIV-AIDS

• Severe malnutrition

• History of hypersensitivity or adverse reactions to fosmidomycin, piperaquine, artesunate and mefloquine

• Treatment with antimalarial and antibacterial agents within the previous 28 days

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Fosmidomycin-Piperaquine

Experimental group

Description:

Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days

Treatment:

Drug: Fosmidomycin-Piperaquine